{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:31:40Z","timestamp":1793320300771,"version":"4.5.0"},"reference-count":24,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2014,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is the first randomized phase III trial to our knowledge combining bevacizumab with chemotherapy in platinum-resistant OC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Eligible patients had measurable\/assessable OC that had progressed &lt; 6 months after completing platinum-based therapy. Patients with refractory disease, history of bowel obstruction, or &gt; two prior anticancer regimens were ineligible. After investigators selected chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel, or topotecan), patients were randomly assigned to single-agent chemotherapy alone or with bevacizumab (10 mg\/kg every 2 weeks or 15 mg\/kg every 3 weeks) until progression, unacceptable toxicity, or consent withdrawal. Crossover to single-agent bevacizumab was permitted after progression with chemotherapy alone. The primary end point was progression-free survival (PFS) by RECIST. Secondary end points included objective response rate (ORR), overall survival (OS), safety, and patient-reported outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The PFS hazard ratio (HR) after PFS events in 301 of 361 patients was 0.48 (95% CI, 0.38 to 0.60; unstratified log-rank P &lt; .001). Median PFS was 3.4 months with chemotherapy alone versus 6.7 months with bevacizumab-containing therapy. RECIST ORR was 11.8% versus 27.3%, respectively (P = .001). The OS HR was 0.85 (95% CI, 0.66 to 1.08; P &lt; .174; median OS, 13.3 v 16.6 months, respectively). Grade \u2265 2 hypertension and proteinuria were more common with bevacizumab. GI perforation occurred in 2.2% of bevacizumab-treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adding bevacizumab to chemotherapy statistically significantly improved PFS and ORR; the OS trend was not significant. No new safety signals were observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2013.51.4489","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T01:41:02Z","timestamp":1395106862000},"page":"1302-1308","source":"Crossref","is-referenced-by-count":1406,"title":["Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial"],"prefix":"10.1200","volume":"32","author":[{"given":"Eric","family":"Pujade-Lauraine","sequence":"first","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hilpert","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Weber","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Reuss","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Poveda","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sorio","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella","family":"Witteveen","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristotelis","family":"Bamias","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deolinda","family":"Pereira","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor Raza","family":"Mirza","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Follana","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bollag","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[{"name":"Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universit\u00e9 Paris Descartes, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris; B\u00e9atrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre L\u00e9on B\u00e9rard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) and Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Kiel; Alexander Reuss..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr518"},{"key":"B2","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/sj.bjc.6601787","volume":"90","author":"Buda A","year":"2004","journal-title":"Br J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3312"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.05.016"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6735"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2183"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.1258"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr149"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2165\/11591720-000000000-00000"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.5345"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0782"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25967"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.1939"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4240"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0109"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0505"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70477-1"},{"key":"B20","first-page":"S18","volume":"49","author":"Monk BJ","year":"2013","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.7685"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.06.004"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.11.009"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.01.011"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2013.51.4489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T19:04:50Z","timestamp":1653505490000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2013.51.4489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,1]]},"references-count":24,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2014,5,1]]}},"alternative-id":["10.1200\/JCO.2013.51.4489"],"URL":"https:\/\/doi.org\/10.1200\/jco.2013.51.4489","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718312260.793493992","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,1]]}}}